– USA, TX – Perimeter Medical Imaging AI, Inc. (TSX: PINK | OTC: PYNKF | FSE: 4PC), – a commercial-stage medical technology company – today announced the appointment of Adrian Mendes as new CEO, effective immediately, succeeding Jeremy Sobotta who resigned, effective June 15, 2023.
The company also announced the appointment of Dr. Josh Vose (MD) to its Board of Directors, effective immediately.
About Dr. Josh Vose
Dr. Vose is an experienced medical device executive and corporate director with a longstanding history in scaling novel surgical technologies, particularly in breast oncology and reconstruction. Most recently, Dr. Vose served as CEO and Board Director at SIA Health, leading the company through its Series B financing, the commercial growth of DuraSorb, and the acquisition by Integra LifeSciences (NASDAQ: IART).
About Adrian Mendes
Adrian Mendes is an experienced technology executive with 25 years of experience building and scaling technology companies across many industries. Most recently, he was COO at Groq Inc, an AI hardware company, which he joined shortly after its formation in 2016 and helped scale to one of the leading startups in that space.
Adrian Mendes said, “The hardworking team at Perimeter has done a wonderful job marrying OCT technology with world-class AI algorithms and developing products that will greatly help cancer surgery patients. I look forward to joining this amazing team as they work to deploy these products broadly and get them into the hands of surgeons everywhere.”
About Perimeter Medical Imaging AI, Inc.
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas.
For more information: https://perimetermed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.